Business Wire · INCY · November 16, 2026
Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa

Get the app for more
Explore stock news, insights and company research.
Get the app → Source: Business Wire ↗